Vaccinex Announces Initiation of Single-Arm Open Label, Phase Ib/2 Study to Evaluate Pepinemab in Combination with Avelumab as Second Line Combination Immunotherapy for Patients with Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
March 21, 2023 08:30 ET
|
Vaccinex, Inc.
The study is intended to assess whether pepinemab can reverse the suppressive tumor microenvironment found in PDAC, thereby facilitating the anti-tumor activity of immune checkpoint blockade ...
BioAegis Therapeutics Announces FDA Clearance of IND for its ‘Inflammation Regulator Protein,’ Gelsolin, for the Treatment of ARDS
January 26, 2023 14:05 ET
|
BioAegis Therapeutics
NORTH BRUNSWICK, N.J., Jan. 26, 2023 (GLOBE NEWSWIRE) -- BioAegis Therapeutics, Inc., a clinical-stage company developing therapies for inflammatory diseases through a portfolio built around plasma...
PharmaNest Announces New Pre-Clinical and Clinical NASH Data to Be Presented at the AASLD - The Liver Meeting Digital Experience™ (TLMdX) 2021
November 12, 2021 08:00 ET
|
PHARMANEST
PRINCETON, N.J., Nov. 12, 2021 (GLOBE NEWSWIRE) -- PharmaNest is a digital pathology and artificial intelligence company that is focused on the development and validation of novel standards for...
Sarcoidosis Drug Market Global Sales are Expected to Grow at a CAGR of 4.3% through 2031
July 09, 2021 09:30 ET
|
insightSLICE
PUNE, India, July 09, 2021 (GLOBE NEWSWIRE) -- The Global Sarcoidosis Drug Market Share, Trends, Analysis and Forecasts, 2021-2031 provides insights on key developments, business strategies,...
Outlook on the Neurological Diseases Treatment Global Market to 2029 - Key Drivers, Challenges and Opportunities
April 29, 2021 07:18 ET
|
Research and Markets
Dublin, April 29, 2021 (GLOBE NEWSWIRE) -- The "Neurological Diseases Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies...
Global Rare Disease Market is estimated to be US$ 547.5 billion by 2030 with a CAGR of 13.1% during the forecast period - by PMI
February 24, 2021 10:35 ET
|
PMI
Covina CA, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Global Rare Disease Market accounted for US$ 161.4 billion in 2020 and is estimated to be US$ 547.5 billion by 2030 and is anticipated to register a CAGR...
Sorrento Announces Subsidiary Company - ADNAB, Inc. - to Develop and Commercialize ADNAB™ Platform Products for Hematological Malignancies and Solid Tumors Based on an Exclusive Technology License From the Mayo Clinic
February 08, 2021 15:21 ET
|
Sorrento Therapeutics, Inc.
The ADNAB™ platform was developed and exclusively licensed to Sorrento by the Mayo Clinic Clinical studies utilizing the ADNAB™ platform are ongoing at the Mayo Clinic; and are evaluating multiple...
Kiniksa Announces Data from U.S. Investigator-Initiated Study of Mavrilimumab in Severe COVID-19 Pneumonia and Hyperinflammation
December 22, 2020 08:00 ET
|
Kiniksa Pharmaceuticals, Ltd.
- Early signal of efficacy with trends toward lower mortality and shorter duration of mechanical ventilation in patients treated with mavrilimumab – - Data from the Phase 2 portion of Kiniksa’s...
Fluidigm COVID-19 Community Connect Program Builds a Network of Testing Partners to Increase Access of Saliva-Based SARS-CoV-2 Testing for Communities
November 17, 2020 08:30 ET
|
Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., Nov. 17, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive...
Kamada Reports Financial Results for Fourth Quarter and Fiscal Year 2019
February 12, 2020 07:00 ET
|
Kamada Ltd.
Total Revenues for Fiscal 2019 were $127.2 million, up 11% as Compared to 2018Gross Profit for Fiscal 2019 was $49.7 Million, up 20% as Compared to 2018Adjusted EBITDA for Fiscal 2019 was $28.5...